Noesion Radarnoesion.ai
Market2026-10-26

Pathos AI secured $237m in a Series E financing round. The round values the company at $3bn post-money. Bristol Myers Squibb led the funding. Existing investors also contributed. Pathos AI will use the funds to scale its Foundry platform. It will also advance four clinical cancer programmes. The programmes include AZD4241, DO-2, JSKN016, and pocenbrodib. Foundry uses AI agents to evaluate drug programme data. It identifies patient sub-populations and redirects clinical trial strategies. The platform also removes high-risk drug projects early.

What it unlocks

Scaling its AI drug development platform and advancing four clinical cancer programmes.

  • $237m Series E round
  • $3bn post-money valuation
  • 4 active clinical cancer programmes

Sources

Send this to someone who needs it

Shares the story and its sources. Nothing about you.

What does this mean for your job?

This is the story as everyone gets it. Once a week we send you the version written for your role — what changed, why it matters for the work you actually do, and one thing to try. Free while we tune it.